ES368207A1 - Gastric hydrochloric acid secretion inhibitor, process for the manufacture of such compounds, pharmaceutical composition and a method for the inhibition of gastric hydrochloric acid secretion - Google Patents

Gastric hydrochloric acid secretion inhibitor, process for the manufacture of such compounds, pharmaceutical composition and a method for the inhibition of gastric hydrochloric acid secretion

Info

Publication number
ES368207A1
ES368207A1 ES368207A ES368207A ES368207A1 ES 368207 A1 ES368207 A1 ES 368207A1 ES 368207 A ES368207 A ES 368207A ES 368207 A ES368207 A ES 368207A ES 368207 A1 ES368207 A1 ES 368207A1
Authority
ES
Spain
Prior art keywords
groups containing
carbon atoms
straight
branched
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES368207A
Other languages
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hassle AB
Original Assignee
Hassle AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hassle AB filed Critical Hassle AB
Publication of ES368207A1 publication Critical patent/ES368207A1/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A procedure for the preparation of derivatives of carbamic acids of the formula ** (See formula) ** in which it is selected from the group consisting of straight and branched alcohol and alkenyl groups containing from 1 to 6 carbon atoms, cycloalkyl and cycloalkenyl groups containing a maximum of 6 carbon atoms, straight and branched alkoxyalkyl groups containing from 2 to 8 carbon atoms, and the radical ** (See formula) ** wherein A represents a bivalent radical selected from the group consisting of straight and branched alcoholic groups containing 1 to 4 carbon atoms, straight and branched alcoholoxy groups containing 1 to 4 carbon atoms and attached to the phenyl nucleus through the oxygen atom, and straight and branched alcoholylene-xyalkylene groups containing from 2 to 8 carbon atoms and are attached to the phenyl nucleus through one carbon atom, and R4 and R5 are the same or different and are selected from the group consisting of hydrogen, hydroxyl and alcohol and alkenyl groups containing 1 to 3 carbon atoms, including isopropyl, alkoxy and alkenoxy groups containing 1 to 3 carbon atoms, including elisopropoxy, straight and branched hydroxyalkyl groups containing 1 to 4 carbon, fluorine, chlorine, bromine, nitro, formyl and amino atoms; and R2 is selected from the group consisting of hydrogen, straight and branched alcohol and alkenyl groups containing from 1 to 4 carbon atoms, cycloalkyl and cycloalkenyl groups containing a maximum of 6 carbon atoms, straight and branched alkoxyalkyl groups containing from 2 to 8 carbon atoms, straight and branched alkoxyalkoxyalkyl groups containing 3 to 9 carbon atoms, and the radical -CO-R3, in which R3 is selected from the group consisting of straight and branched alcohol and alkenyl groups containing 1 to 4 carbon atoms, straight and branched alkoxy and alkenoxy groups containing 1 to 4 carbon atoms, straight and branched alkoxyalkoxy groups containing 2 to 8 carbon atoms, straight and branched alkoxyalkoxyalkoxy groups containing 3 to 9 straight and branched carbon atoms, alkoxyalkyl groups containing 2 to 8 carbon atoms, and the radical ** (See formula) ** Wherein R4 and R5 are as defined above, and B represents a valence line or a bivalent radical selected from the group consisting of alcohol-ethoxy groups containing 1 to 4 carbon atoms and attached to the phenyl nucleus via of a carbon atom, excluding the compounds of the formula ** (See formula) ** wherein R1 represents CH3-, C2H5-, (CH3) 2CH-, (CH3) 3CC6H5CH2-, C6H5CH2CH2CH2-, CH2 = CHCH2-, or C6H5OCH2CH2, and excluding the compounds of the formula Q-O-C-NH- CH2CH2OQ wherein Q represents CH3-, C2H5- or C4H9-; characterized by the addition of a hydroxy compound of the formula R1-OH II wherein R1 has the meaning specified above, to an isocyanate of the formula O = C = N - CH2CH2OR2 III wherein R2 has the meaning specified above, for the formation of a compound of formula I. (Machine-translation by Google Translate, not legally binding)
ES368207A 1968-06-11 1969-06-10 Gastric hydrochloric acid secretion inhibitor, process for the manufacture of such compounds, pharmaceutical composition and a method for the inhibition of gastric hydrochloric acid secretion Expired ES368207A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2778768A GB1279412A (en) 1968-06-11 1968-06-11 Gastric hydrochloric acid secretion inhibitor, process for the manufacture of such compounds, pharmaceutical composition and a method for the inhibition of gastric hydrochloric acid secretion

Publications (1)

Publication Number Publication Date
ES368207A1 true ES368207A1 (en) 1972-04-16

Family

ID=10265313

Family Applications (3)

Application Number Title Priority Date Filing Date
ES368207A Expired ES368207A1 (en) 1968-06-11 1969-06-10 Gastric hydrochloric acid secretion inhibitor, process for the manufacture of such compounds, pharmaceutical composition and a method for the inhibition of gastric hydrochloric acid secretion
ES71388702A Expired ES388702A1 (en) 1968-06-11 1971-02-27 Gastric hydrochloric acid secretion inhibitor, process for the manufacture of such compounds, pharmaceutical composition and a method for the inhibition of gastric hydrochloric acid secretion
ES388703A Expired ES388703A1 (en) 1968-06-11 1971-02-27 Gastric hydrochloric acid secretion inhibitor, process for the manufacture of such compounds, pharmaceutical composition and a method for the inhibition of gastric hydrochloric acid secretion

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES71388702A Expired ES388702A1 (en) 1968-06-11 1971-02-27 Gastric hydrochloric acid secretion inhibitor, process for the manufacture of such compounds, pharmaceutical composition and a method for the inhibition of gastric hydrochloric acid secretion
ES388703A Expired ES388703A1 (en) 1968-06-11 1971-02-27 Gastric hydrochloric acid secretion inhibitor, process for the manufacture of such compounds, pharmaceutical composition and a method for the inhibition of gastric hydrochloric acid secretion

Country Status (11)

Country Link
AT (6) AT293430B (en)
BE (1) BE734033A (en)
BR (1) BR6909672D0 (en)
CH (2) CH525193A (en)
DE (1) DE1929416A1 (en)
DK (1) DK126035B (en)
ES (3) ES368207A1 (en)
FR (2) FR2010650B1 (en)
GB (1) GB1279412A (en)
IE (1) IE33149B1 (en)
NL (1) NL6908843A (en)

Also Published As

Publication number Publication date
CH539021A (en) 1973-08-31
DK126035B (en) 1973-06-04
AT298667B (en) 1972-05-25
AT293428B (en) 1971-10-11
NL6908843A (en) 1969-12-15
ES388702A1 (en) 1973-05-16
CH525193A (en) 1972-07-15
AT293430B (en) 1971-10-11
IE33149L (en) 1969-12-11
FR2010650A1 (en) 1970-02-20
IE33149B1 (en) 1974-04-03
AT294849B (en) 1971-12-10
ES388703A1 (en) 1974-02-16
DE1929416A1 (en) 1970-07-16
AT292012B (en) 1971-08-10
FR2010650B1 (en) 1975-01-10
BR6909672D0 (en) 1973-03-13
GB1279412A (en) 1972-06-28
AT293429B (en) 1971-10-11
BE734033A (en) 1969-11-17
FR2140246A1 (en) 1973-01-12

Similar Documents

Publication Publication Date Title
ES8500265A1 (en) Novel pharmaceutical compositions.
ES8304534A1 (en) preparation, compositions and intermediates.
ES435110A1 (en) Process for the manufacture of 7-beta-amino-cephem-3-ol-4-carboxylic acid compounds
ES474215A1 (en) Imidazolylethylene-oxyalkyloxy derivatives and their thio analogues, methods for their preparation and pharmaceutical compositions containing them.
ES386068A1 (en) 5-phenyl-isoxazole-3-carboxylic acids and their derivatives
ES419936A1 (en) 1-hydroxy-1-((4'-hydroxy-3'aminosulfonamido)-phenyl)-2-amino-ethanes and salts
ES368207A1 (en) Gastric hydrochloric acid secretion inhibitor, process for the manufacture of such compounds, pharmaceutical composition and a method for the inhibition of gastric hydrochloric acid secretion
ES406858A1 (en) (5-nitro-2-furyl)-pyridines
ES8203867A1 (en) Benzothiazole derivatives, pharmaceutical compositions containing them and process for their preparation.
ES8300685A1 (en) Novel pentapeptides, processes for their production, pharmaceutical compositions comprising said pentapeptides and their use.
GB1241637A (en) Improvements in or relating to anti-inflammatory compositions
PT83786A (en) NEW BASIC SUBSTITUTED PYRIDINE COMPOUNDS METHOD FOR THE PRODUCTION THEREOF THE MEDICAMENT CONTAINING THEY AND THEIR USE
ES407519A1 (en) 2-(5'-nitro-2'-furyl)-thieno(2,3-d)pyridines and salts thereof
ES8103056A1 (en) Prostaglandin analogue imidazole derivatives, processes for their preparation and a pharmaceutical composition containing them.
ES389921A1 (en) N-(hydroxy-or methoxy-alkyl)-2-(n'-(hydroxy or methoxy-alkyl)-phenyl-amino)-imidazolines-(2) and salts thereof
ES449425A1 (en) Aminopyrrole derivatives
ES274330A1 (en) Procedure for the preparation of new compounds of 1,5-benzodioxepano (Machine-translation by Google Translate, not legally binding)
ES8407475A1 (en) Hydroxyimino and alkoxyimino derivatives of 1,4-dihydropyridine, process for the preparation thereof and pharmaceutical composition therefrom.
ES412068A1 (en) Xylidides
GB1426514A (en) Basic esters and process for the preparation thereof
ES270557A1 (en) Procedure for the preparation of new derivatives of the alquilbenzoico acid (Machine-translation by Google Translate, not legally binding)
ES466305A1 (en) Benzopyran derivative*its production and pharmacological compositions containing same
ES453183A1 (en) Chlorine-substituted vinylaminobenzoic acid compounds and plant growth regulant compositions
ES428132A1 (en) Alkylated pregnanes
ES396175A1 (en) Phenylethanolamine derivatives